HPV-LR
Alternative name:
Human papillomavirus (HPV)- Low Risk , HPV RNA ISH Low Risk Cocktail
Methodology
In Situ Hybridization (ISH)
Test Description and clinical significance
Disease:
Low risk, or non-oncogenic, types of the virus rarely cause precancerous lesions, though they may still cause cellular changes.
This test provides detection of human papilloma virus E6/E7 mRNA, histological localization of HPV within the tissue, and differentiation of low-risk vs. high-risk subtypes in formalin-fixed paraffin-embedded tissues. Positive results in this assay provide evidence of transcriptional activation of viral E6/E7 oncogenes and support the diagnosis of active infection. Studies have shown RNA ISH to have greater sensitivity and specificity than DNA ISH for HPV detection. RNA ISH may be useful in resolving cases with p16 overexpression that tested negative for HPV DNA by other methods. Testing is commonly performed on tissues of the uterine cervix, anus, and head and neck, particularly the oropharynx. HPV ISH may help resolve cervical cases with morphology discrepant from HPV status as determined from cytology specimens. Positive HPV status is associated with improved overall survival in oropharyngeal squamous cell carcinoma.
Specimen Requirements
Collection:
FFPE/un-stained slides/Fresh tissue in formalin
Stability:
Room temperature
Unacceptable Conditions:
Unlabeled specimen/specimen left unfixed
for extended periods
Storage & Transport
Room Temperature
CPT(s)
Partial panel: 88365x1 for first component/cocktail, 88364x1 for second component/cocktail.
New York Approved
YES
TAT
7 days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
